tirzepatide 2.5 mg weight loss data dose chart: complete dosing schedule for Tirzepatide - no weight loss

LY3437943 (Retatrutide): discovery to clinical proof of concept (triple GLP-1/GIP/glucagon agonist, preclinical mechanism) Nature Reviews Endocrinology (2024) Multi-receptor agonists for metabolic disease (mechanism of GLP-1/GIP/glucagon co-activation) Diabetes Care (2024) Incretin-based therapies: GLP-1, GIP, and glucagon receptor pharmacology (metabolic pathways, energy expenditure) NEJM (2023) Supplementary Material Jastreboff et al

By inhibiting glucagon, GLP-1 prevents the excessive release of glucose from the liver, thus keeping blood sugar levels from becoming excessively high

If your weekly weight average has not decreased by at least 1%, your caloric intake has not measurably dropped, and your hunger scores are unchanged, the microdose is likely sub-therapeutic for you

So the foundation of eating on a GLP-1 is prioritizing nutrient-dense foods over empty calories